Best Researcher Award

Shiji Fang
Lishui Central Hospital, China

Shiji Fang
Affiliation	Lishui Central Hospital
Country	China
Scopus ID	57192204982
Documents	91
Citations	2,574
h-index	27
Subject Area	Medicine
Event	International Research Hypothesis Excellence Award
ORCID	0009-0004-4998-5039

Shiji Fang is a medical researcher affiliated with Lishui Central Hospital in China whose indexed research profile reflects sustained scholarly activity in biomedical and translational medicine. The available Scopus-derived profile records 91 documents, 2,574 citations and an h-index of 27, indicating a substantial body of indexed research and citation activity. [1][2]

Abstract

Shiji Fang’s research profile is situated within medicine and includes a substantial body of indexed scholarly work. The supplied publication record highlights research at the intersection of cancer biology, tumor microenvironment, immunotherapy and nanomedicine. Recent studies address mechanisms and therapeutic approaches involving immunogenic cell death, reactive oxygen species, endoplasmic reticulum stress, cellular senescence, copper homeostasis, ferroptosis, cuproptosis, chemoembolization and MRI-guided therapeutic systems. [1] [2]

Keywords

Shiji Fang; Best Researcher Award; Medicine; cancer research; hepatocellular carcinoma; immunotherapy; nanomedicine; immunogenic cell death; ferroptosis; cuproptosis; tumor biology; therapeutic delivery; translational medicine; oxidative stress; endoplasmic reticulum stress.

Introduction

Contemporary cancer research increasingly integrates molecular oncology with materials science, immunology and targeted therapeutic delivery. Hepatocellular carcinoma in particular presents a complex therapeutic environment in which tumor heterogeneity, immune suppression and resistance mechanisms can limit treatment effectiveness. Research that investigates interactions among tumor cells, immune pathways and therapeutic nanoplatforms therefore forms an important component of translational biomedical investigation.[2] [3]

Research Profile

The supplied Scopus profile identifies Shiji Fang with Author ID 57192204982 and lists Lishui Central Hospital, China, as the institutional affiliation. The profile is associated with the subject area of Medicine and records 91 indexed documents, 2,574 citations and an h-index of 27. [1]

Research characteristics

• Primary discipline: Medicine.
• Institutional affiliation: Lishui Central Hospital, China.
• Scopus Author ID: 57192204982.
• Indexed documents: 91.
• Reported citations: 2,574.
• Reported h-index: 27.
• Major themes represented: cancer biology, hepatocellular carcinoma, immunotherapy, nanomedicine and regulated cell-death mechanisms.

Research Contributions

The supplied publications indicate several connected areas of research contribution. One strand examines how natural or bioactive compounds can influence cancer-cell death and stress-response pathways. The 2025 article on astragalin investigates immunogenic cell death in liver cancer in connection with NQO2, reactive oxygen species and endoplasmic reticulum stress. [2]

A second strand concerns the integration of cellular senescence with immune activation. The study published in Advanced Science describes a biomimetic nanomedicine approach designed around senescence-modulated immune activation and its potential relationship with immunotherapy efficacy in hepatocellular carcinoma. [3]

Publications

The following selected publications are taken from the supplied Scopus-derived research information. The list emphasizes recent 2025 articles and includes DOI identifiers where provided.

1. Astragalin induces immunogenic cell death in liver cancer by targeting NQO2 to promote ROS-mediated endoplasmic reticulum stress pathway. Free Radical Biology and Medicine.
2. Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science.
3. Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy. Journal of Nanobiotechnology.
4. Corrigendum to “Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma”. Cellular Signalling.

Research Impact

The supplied bibliometric indicators provide a quantitative view of the visibility of the research record. With 2,574 reported citations and an h-index of 27 across 91 indexed documents, the profile demonstrates sustained citation activity within the indexed scholarly literature. [1] Bibliometric measures should nevertheless be interpreted alongside publication quality, methodological rigor, authorship contributions and the substantive influence of individual studies.

Award Suitability

The Best Researcher Award within the International Research Hypothesis Excellence Award framework can be assessed using evidence concerning research productivity, scholarly visibility, thematic contribution and relevance to the broader research community. The supplied profile provides several measurable indicators, including 91 indexed documents, 2,574 citations and an h-index of 27. [1]

Conclusion

Shiji Fang’s supplied academic profile presents an established research record in Medicine, with affiliation to Lishui Central Hospital in China and a Scopus Author ID of 57192204982. The reported 91 documents, 2,574 citations and h-index of 27 provide quantitative indicators of scholarly activity and citation visibility. [1]

External Links

• ORCID Profile
• Scopus Author Profile
• Award Website

References

1. Elsevier. (n.d.). Scopus author details: Shiji Fang, Author ID 57192204982. Scopus.
   https://www.scopus.com/pages/authors/57192204982
2. Zheng, L., Zhao, Z., Chen, L., Yang, W., Ercolani, G., Qin, P., Lin, B., Han, M., Weng, Q., Zhang, Y., et al. (2025). Astragalin induces immunogenic cell death in liver cancer by targeting NQO2 to promote ROS-mediated endoplasmic reticulum stress pathway. Free Radical Biology and Medicine.
   https://doi.org/10.1016/j.freeradbiomed.2025.07.047
3. Fang, S., Zheng, L., Lin, B., Chen, J., Hou, D., Ding, Y., Han, M., Qin, P., Wang, M., Guo, X., et al. (2025). Biomimetic Nanomedicine for Senescence-Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science.
   https://doi.org/10.1002/advs.202517792
4. Liang, X., Fang, S., Xin, Y., Lei, J., Wang, W., Wei, Y., Li, W., Li, C., Tang, H., Wei, X., et al. (2025). Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy. Journal of Nanobiotechnology.
   https://doi.org/10.1186/s12951-025-03722-2
5. Chen, M., Chen, Y., Chen, W., Chen, X., Guo, X., Yu, J., Guo, X., Wang, M., Zhang, X., Hu, Q., et al. (2025). Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor. Acta Biomaterialia.
   https://doi.org/10.1016/j.actbio.2025.04.042
6. Chen, X., Zhang, F., Lu, C., Wu, R., Yang, et al. (2025). Lactate-Fueled Theranostic Nanoplatforms for Enhanced MRI-Guided Ferroptosis Synergistic with Immunotherapy of Hepatocellular Carcinoma. ACS Applied Materials and Interfaces.
   https://doi.org/10.1021/acsami.4c21890